title: Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.
abstract: Highly active antiretroviral treatment (HAART) was given early to 64 patients with symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of analysis, patients had been followed up for 9-21 months. No patient had died or developed an AIDS-defining event. Survival analysis showed that by month 21 the proportion of patients with plasma HIV-1 RNA <50 copies/mL was 72% (95% confidence interval, 58%-95%) in intention-to-treat analysis. After 18 months of treatment, 50% of the patients with undetectable plasma HIV-1 RNA also had undetectable HIV-1 RNA in peripheral blood mononuclear cells (PBMC). Only 1 of 3 patients had undetectable HIV-1 RNA in lymphoid tissue, while all patients had quantifiable HIV-1 DNA both in PBMC and lymphoid tissue. The median CD4 lymphocyte increase from baseline was 230 cells/microL. These preliminary results support the use of HAART in patients with primary HIV-1 infection.
authors.affiliation: Service de Maladies Infectieuses et Tropicales, CHU de Besançon-Hôpital Saint-Jacques, F-25030 Besancon Cedex, France. bruno.hoen@univ-fcomte.fr
authors.forename: B
authors.initials: B
authors.lastname: Hoen
authors.forename: B
authors.initials: B
authors.lastname: Dumon
authors.forename: M
authors.initials: M
authors.lastname: Harzic
authors.forename: A
authors.initials: A
authors.lastname: Venet
authors.forename: B
authors.initials: B
authors.lastname: Dubeaux
authors.forename: C
authors.initials: C
authors.lastname: Lascoux
authors.forename: Y
authors.initials: Y
authors.lastname: Bourezane
authors.forename: J M
authors.initials: JM
authors.lastname: Ragnaud
authors.forename: A
authors.initials: A
authors.lastname: Bicart-See
authors.forename: F
authors.initials: F
authors.lastname: Raffi
authors.forename: L
authors.initials: L
authors.lastname: Beauvais
authors.forename: H
authors.initials: H
authors.lastname: Fleury
authors.forename: D
authors.initials: D
authors.lastname: Séréni
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016001:Confidence Intervals; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D012367:RNA, Viral / Q000097:blood; D019438:Ritonavir / Q000627:therapeutic use*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D019259:Lamivudine; D015215:Zidovudine; D019438:Ritonavir